Subscribe
Subscribe

  • Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

Biocartis: ready for commercial boom

Biocartis CSO Geert Maertens gives an overview of the progress and future prospects of the company.

Strengthening communication in biotech companies

Many biotech management teams fail to reach out to investors in a clear and appealing way.

Janssen R&D focus enforced with new managing director

Unlocking patient data from medical reports

Designer yeast: synthetic genome closer to reality

Five entirely synthetic yeast chromosomes were created this year. By 2018 every chromosome is expected to have a synthetic couterpart, resulting in en entirely synthetic genome.

Ablynx finishes preclinical work on osteoarthritis nanobody for Merck

The first nanobody from the Ablynx-Merck collaboration reaches clinical development, triggering a €15m milestone payment to Ablynx.

World’s First Thin-Silicon Implantable Chip for High-Precision Haptic Prosthetics

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

While C-Cure had failed an essential phase 3 clinical trial in June last year, the trial identified a subgroup of patients where the drug was effective nonetheless. Based on this fact, C-Cure now receives Fast Track designation from the US drug policy maker.

Biocartis announces its new CEO

Biocartis has revealed its pick for its vacant top function.

Progranulin shortage could cause frontotemporal dementia

  • Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

Biocartis: ready for commercial boom

Biocartis CSO Geert Maertens gives an overview of the progress and future prospects of the company.

Strengthening communication in biotech companies

Many biotech management teams fail to reach out to investors in a clear and appealing way.

Janssen R&D focus enforced with new managing director

Unlocking patient data from medical reports

Designer yeast: synthetic genome closer to reality

Five entirely synthetic yeast chromosomes were created this year. By 2018 every chromosome is expected to have a synthetic couterpart, resulting in en entirely synthetic genome.

Ablynx finishes preclinical work on osteoarthritis nanobody for Merck

The first nanobody from the Ablynx-Merck collaboration reaches clinical development, triggering a €15m milestone payment to Ablynx.

World’s First Thin-Silicon Implantable Chip for High-Precision Haptic Prosthetics

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

While C-Cure had failed an essential phase 3 clinical trial in June last year, the trial identified a subgroup of patients where the drug was effective nonetheless. Based on this fact, C-Cure now receives Fast Track designation from the US drug policy maker.

Biocartis announces its new CEO

Biocartis has revealed its pick for its vacant top function.

Progranulin shortage could cause frontotemporal dementia